bioterror
deliv
individu
group
religi
polit
bioterror
agenda
vaccin
excel
technic
feasibl
defens
threat
potenti
limit
postattack
diseas
spread
vaccin
readi
even
consid
deterr
develop
use
specif
bioterror
agent
reduc
potenti
effect
henc
decreas
util
weapon
even
though
vaccin
probabl
benefici
therapi
physician
provid
patient
still
signific
roadblock
develop
licens
new
vaccin
roadblock
includ
biolog
technolog
issu
larg
extent
major
roadblock
difficulti
prepar
safe
effect
product
high
cost
test
almost
unavoid
consequ
occasion
matter
infrequ
minor
advers
event
develop
vaccin
requir
million
dollar
take
long
time
get
phase
iii
trial
profit
margin
invest
less
success
drug
must
taken
daili
basi
cholesterollow
statin
deriv
addit
vaccin
administ
healthi
individu
side
effect
even
unrel
vaccin
make
manufactur
target
lawsuit
even
beyond
develop
cost
vaccin
program
expens
vaccin
perish
must
administ
profession
may
accept
populac
without
defin
urgent
microbi
threat
clearli
need
vaccin
strategi
integr
sustain
flexibl
consist
challeng
develop
new
vaccin
new
mechan
evalu
fund
vaccin
even
way
administ
vaccin
sinc
immun
respons
evolv
provid
protect
infecti
diseas
optim
develop
protect
immun
respons
vaccin
mimic
step
process
elicit
establish
natur
immun
late
part
centuri
cell
identifi
ultim
control
immun
respons
vaccin
begin
design
activ
cell
centuri
recogn
import
innat
respons
especi
dendrit
cell
dc
optim
develop
specif
immun
respons
innat
immun
respons
progress
seri
stage
orchestr
dc
conduct
cell
appropri
cytokin
deliv
activ
cell
antibodi
dc
essenti
initi
immun
respons
present
antigen
cell
determin
natur
immun
respons
deliv
cell
better
understand
biolog
activ
dc
cytokin
produc
dc
mechan
antigen
present
foster
new
develop
vaccin
design
formul
unfortun
dc
biolog
still
confus
sever
reason
first
mous
human
dc
differ
differ
activ
requir
cell
surfac
receptor
second
may
five
differ
subset
dc
base
surfac
marker
includ
two
major
subset
distinguish
express
myeloid
plasmacytoid
dendrit
cell
characterist
develop
dc
discuss
greater
extent
review
natur
infect
immatur
dc
peripheri
constantli
take
protein
survey
antigen
environ
upon
activ
interact
structur
microbi
pathogen
cell
activ
produc
cytokin
begin
matur
antigenpres
cell
apc
microbi
structur
term
pathogenassoci
molecular
pattern
pamp
gener
repetit
structur
includ
extracellular
bacteri
structur
nucleic
acid
pamp
recogn
protein
tolllik
receptor
tlr
present
cell
surfac
within
endocyt
vesicl
cytoplasm
pamp
receptor
lipopolysaccharid
tolllik
receptor
peptidoglycan
flagellin
singleand
doublestrand
rna
undermethyl
guanosineand
cytosinecontain
oligodeoxynucleotid
cpg
tlr
ligand
also
potent
adjuv
immun
respons
imiquimod
resiquimod
exampl
smallmolecul
artifici
ligand
licens
antivir
usag
wart
recent
recogn
potenti
adjuv
myeloid
dc
princip
antigenpres
cell
determin
natur
tcell
respons
antigen
cell
express
respond
pamp
human
plasmacytoid
dc
express
respond
primarili
singleand
doublestrand
rna
cpg
viru
infect
produc
alpha
interferon
myeloid
plasmacytoid
dc
respond
imiquimod
resiquimod
signal
occupi
tlr
initi
matur
dc
surveyor
peripheri
cytokineproduc
antigenpres
cell
matur
dc
ceas
intern
extracellular
protein
upregul
express
molecul
involv
antigen
present
move
lymph
node
present
antigen
cell
natur
tlr
signal
determin
cytokin
dc
produc
henc
type
respons
cell
initi
combin
antibodi
cellular
immun
produc
part
respons
first
earli
local
antibodyand
cellmedi
respons
character
direct
interleukin
produc
myeloid
cell
gamma
interferon
produc
nk
nkt
cell
alpha
interferon
produc
immatur
plasmacytoid
dendrit
cell
respons
herp
simplex
viru
hsv
tlr
stimul
promot
respons
either
directli
indirectli
stimul
nk
cell
produc
gamma
interferon
combin
antibodyand
cellmedi
respons
gener
respons
necessari
control
intracellular
viral
bacteri
parasit
fungal
infect
respons
predominantli
antibodi
respons
aris
absenc
parasit
worm
infect
respons
direct
predominantli
interleukin
antibodi
often
suffici
control
viremia
bacteremia
extracellular
infect
respons
antagonist
cytokin
produc
respons
prevent
initi
respons
immun
vaccin
establish
respons
prevent
develop
respons
may
even
exacerb
diseas
follow
infect
would
definit
case
vaccin
tuberculosi
mycobacterium
lepra
leishmaniasi
respons
associ
sever
diseas
interestingli
antagonist
natur
immun
respons
also
use
develop
vaccin
curtail
aberr
immun
respons
describ
later
myocard
dc
capac
present
antigen
peptid
extracellular
antigen
eg
viral
tumor
protein
cell
major
histocompat
complex
class
mhci
mhcii
molecul
peptid
amino
acid
long
degrad
proteosom
transport
endoplasm
reticulum
er
transport
associ
process
bind
within
pocket
top
mhci
heavi
chain
addit
subunit
allow
mhci
molecul
progress
golgi
apparatu
cell
surfac
contrast
bind
groov
top
mhcii
molecul
fill
invari
chain
molecul
within
er
prevent
acquisit
antigen
peptid
er
mhcii
molecul
normal
receiv
peptid
present
transport
er
endosom
peptid
phagocytos
protein
replac
invari
chain
newli
fill
mhcii
molecul
deliv
cell
surfac
morerec
find
demonstr
exogen
peptid
also
find
way
onto
mhci
molecul
cross
present
pathway
protein
viral
tumor
apoptot
phagocytos
cell
degrad
leav
endosom
vesicl
find
way
endoplasm
reticulum
decor
mhci
molecul
mimick
manipul
pathway
provid
mean
enhanc
immunogen
peptid
vaccin
combin
increas
understand
immun
respons
technolog
advanc
molecular
biolog
instrument
basi
mani
new
develop
vaccin
design
use
advanc
genom
proteom
structur
biolog
also
provid
new
candid
peptid
vaccin
knowledg
genet
sequenc
bacteri
speci
technolog
avail
predict
appropri
immunogen
make
vaccin
use
revers
vaccinolog
research
chiron
develop
new
group
b
neisseria
meningitidi
vaccin
manner
approach
use
develop
vaccin
start
hypothesi
bacteri
cell
surfac
molecul
elicit
protect
antibodi
respons
potenti
immunogen
identifi
cell
surfac
molecul
bacteri
genet
sequenc
silico
comput
surfac
locat
protein
confirm
gene
protein
clone
express
use
immunoassay
sera
obtain
convalesc
infect
verifi
immunogen
protein
suffici
protein
produc
immun
anim
two
outer
membran
protein
n
meningitidi
demonstr
induc
protect
challeng
vaccin
use
protein
less
type
specif
capsular
polysaccharid
vaccin
requir
conjug
carrier
protein
elicit
complet
respons
enhanc
adjuv
better
understand
dendrit
cell
tcell
activ
regul
foster
develop
use
new
adjuv
cytokin
chemokin
costimulatori
molecul
vaccin
formul
enhanc
immunogen
develop
memori
direct
type
respons
elicit
vaccin
adjuv
definit
enhanc
immunogen
vaccin
promot
uptak
immunogen
activ
dc
initi
immun
respons
natur
adjuv
includ
tlr
ligand
cytokin
chemokin
produc
respons
natur
stimul
artifici
adjuv
enhanc
immunogen
antigen
activ
cytokin
respons
similar
tlr
activ
dc
promot
uptak
immunogen
ideal
adjuv
promot
natur
immun
respons
less
immunogen
classic
adjuv
vaccin
recent
fdaapprov
adjuv
alum
alum
provid
particl
upon
vaccin
precipit
although
precipit
onto
alum
promot
uptak
immunogen
alum
poor
activ
dc
induc
product
result
alumbas
vaccin
initi
antibodi
respons
complet
freund
adjuv
cfa
power
adjuv
consist
inactiv
bacillu
bcg
strain
mycobacterium
bovi
contain
mixtur
differ
tlr
ligand
miner
oil
solut
emulsif
immunogen
miner
oil
provid
depot
slow
antigen
releas
promot
phagocytosi
bcg
strong
activ
dc
respons
cfa
approv
human
usag
newer
adjuv
approv
use
human
vaccin
includ
monophosphoryl
lipid
mpl
includ
endotoxinlik
compon
bacteri
lipopolysaccharid
montanid
seppic
consist
wellcharacter
mixtur
oillik
compon
complet
freund
adjuv
without
bcg
consist
squalen
microfluid
oil
water
emuls
saponin
deriv
also
use
extens
adjuv
adjuv
activ
repres
cfa
greater
safeti
combin
alum
adjuv
mpl
enhanc
immunogen
vaccin
combin
alum
mpl
use
human
papillomaviru
hpv
viruslik
particl
vlp
vaccin
herp
simplex
viru
glycoprotein
subunit
vaccin
develop
glaxosmithklin
jeffrey
ulmer
chiron
describ
sever
differ
approach
chiron
taken
develop
new
type
adjuv
addit
adjuv
basi
discoveri
small
molecul
imiquimod
bind
activ
tlr
initi
largescal
vitro
screen
procedur
discov
smallmolecul
immun
potenti
possibl
adjuv
screen
procedur
base
abil
molecul
promot
tumor
necrosi
factor
alpha
product
spleen
cell
prepar
procedur
alreadi
identifi
sever
candid
adjuv
take
advantag
antigen
present
although
peptid
antigen
small
size
often
limit
abil
initi
immun
respons
classic
peptid
would
attach
larger
protein
carrier
keyhol
limpet
hemocyanin
increas
visibl
dc
howev
incorpor
addit
epitop
carrier
immunogen
respons
usual
antibodi
respons
peptid
interest
sever
approach
discuss
meet
promot
immunogen
peptid
manipul
interact
mhc
molecul
tcell
receptor
dc
dan
zimmerman
celsci
corp
ken
rosenth
northeastern
ohio
univers
colleg
medicin
describ
leap
ligand
epitop
antigen
present
system
technolog
convert
small
peptid
immunogen
technolog
convert
epitopecontain
peptid
small
elicit
immun
respons
immunogen
addit
technolog
also
determin
type
immun
respons
initi
leap
vaccin
leap
approach
util
small
peptid
approxim
amino
acid
obtain
mhci
mhcii
molecul
immun
cell
bind
ligand
icbl
facilit
immunogen
interact
mhc
molecul
tcell
receptor
icbl
coval
attach
triglycin
linker
epitopecontain
peptid
vaccin
use
technolog
prepar
peptid
tuberculosi
plasmodium
speci
herp
simplex
viru
g
icbl
peptid
beta
chain
mhcii
promot
respons
attach
peptid
j
icbl
peptid
obtain
upon
coval
attach
promot
respons
epitop
unlik
larg
protein
carrier
detect
immun
respons
j
g
icbl
peptid
detect
protect
immun
elicit
mice
attach
j
icbl
epitop
small
amino
acid
hsv
protein
glycoprotein
b
glycoprotein
vaccin
elicit
tcell
respons
suffici
protect
jicblbas
vaccin
appear
activ
cell
product
antibodi
epitop
observ
upon
antigen
infecti
challeng
primeboost
type
manner
gicblbas
leap
vaccin
elicit
antibodi
respons
without
need
boost
protect
hsv
daniela
cihakova
john
hopkin
school
medicin
report
leap
vaccin
also
use
manipul
immun
respons
prevent
treat
experiment
autoimmun
myocard
immun
responsemedi
diseas
immun
myosinderiv
peptid
attach
j
icbl
elicit
respons
significantli
reduc
vol
minireview
march
guest
http
cviasmorg
incid
sever
myocard
leap
approach
may
use
modul
immun
diseas
robert
humphrey
generex
describ
two
approach
enhanc
immunogen
manipul
interact
antigen
peptid
mhcii
molecul
extens
analysi
interact
invari
chain
mhcii
molecul
fouraminoacid
peptid
name
iikey
bind
open
groov
mhcii
molecul
accept
peptid
identifi
attach
epitop
iikey
threeaminoacid
spacer
creat
peptid
open
groov
mhcii
molecul
surfac
apc
promot
bind
peptid
epitop
within
groov
apc
present
tether
antigen
cell
immun
perform
use
peptid
dna
vaccin
express
peptid
sequenc
iikey
epitop
vaccin
vaccin
influenza
viru
epitop
includ
epitop
virus
develop
use
technolog
anoth
approach
express
invari
chain
dc
suppress
antisens
rna
technolog
small
interf
rna
allow
mhcii
molecul
acquir
antigen
peptid
endoplasm
reticulum
like
mhci
molecul
display
cell
surfac
given
dna
vaccin
viral
tumor
peptid
small
interf
rna
invari
chain
enhanc
tcellmedi
respons
allow
apc
present
antigen
peptid
cell
mhci
molecul
also
cell
mhcii
molecul
recogn
dc
ultim
apc
appropri
stimul
dc
determin
natur
subsequ
immun
respons
brian
czerniecki
univers
pennsylvania
describ
excit
approach
colleagu
develop
dcbase
antibreast
tumor
vaccin
vaccin
util
dc
gener
rapidli
effici
autolog
monocyt
depend
upon
stimuli
monocyt
convert
dc
dc
cell
gener
matur
monocyt
dc
presenc
gamma
interferon
ligand
resiquimod
demonstr
optim
stimul
antitumor
cell
requir
cell
earli
clinic
trial
immun
vitrogener
cell
incub
promot
tcell
respons
tumor
cell
clinic
evid
antitumor
respons
breast
size
matter
particl
size
microb
preferenti
taken
dc
macrophag
go
beyond
alum
concept
chiron
develop
microparticl
chemic
modifi
poli
lactidecoglycolid
plg
microparticl
either
neg
posit
surfac
charg
carri
protein
dna
respect
particl
diamet
approxim
size
bacterium
potenc
proteindecor
particl
enhanc
coadministr
cpg
oligodeoxynucleotid
potent
activ
exampl
immunogen
outer
membran
protein
neisseria
meningitidi
enhanc
adhes
posit
charg
particl
coadministr
cpg
oligodeoxynucleotid
significantli
boost
respons
antibodi
product
plgmening
b
protein
plu
cpg
vaccin
time
greater
freund
adjuv
time
alon
time
cpg
plu
time
adsorb
alum
posit
charg
plg
particl
use
enhanc
activ
dna
vaccin
immun
plghepat
c
viru
dna
plghiv
dna
vaccin
gener
thousandfoldhigh
antibodi
titer
fewer
immun
dna
alon
use
particl
approach
ronald
elli
id
biomed
describ
develop
noninfecti
particlebas
influenza
vaccin
administ
aerosol
intranas
proteosom
influenza
vaccin
fluinsur
incorpor
influenza
viru
hemagglutinin
neuraminidas
protein
particl
contain
neisseria
meningitidi
outer
membran
protein
prepar
outer
membran
protein
act
adjuv
particul
form
vaccin
enhanc
uptak
immunogen
singl
dose
vaccin
effect
elicit
mucos
secretori
immunoglobulin
protect
influenza
viru
challeng
human
volunt
aerosoladminist
influenza
vaccin
offer
straightforward
approach
custom
synthesi
annual
influenza
vaccin
ann
schuind
glaxosmithklin
describ
develop
clinic
trial
vlpbase
dival
vaccin
human
cervic
carcinomaassoci
papillomaviru
strain
took
advantag
mother
natur
let
genet
engin
vitroproduc
larg
capsid
protein
hpv
type
selfassembl
vlp
nm
vlp
readili
taken
dc
macrophag
enhanc
immunogen
viral
protein
women
n
year
age
receiv
three
dose
bival
vaccin
consist
vlp
proprietari
adjuv
protect
acquisit
hpv
diseas
persist
hpv
diseas
although
present
meet
merck
develop
similar
vaccin
receiv
fda
approv
june
prevent
infect
prevent
cervic
cancer
vlp
also
modifi
gener
protect
antibodi
diseas
martin
bachman
cyto
biotechnolog
discuss
use
chemic
modifi
vlp
make
vaccineinduc
therapi
smoke
hypertens
chemic
affix
nicotin
onto
surfac
bacteriophag
immunogen
stabl
easi
inexpens
make
develop
nicotinemodifi
elicit
neutral
antibodi
inhibit
uptak
nicotin
brain
limit
reward
smoke
result
phase
studi
indic
success
reduct
smoke
individu
develop
high
titer
antinicotin
antibodi
blood
respons
vaccin
technolog
appli
develop
antibodymedi
therapi
diseas
initi
work
begun
vaccin
prevent
hypertens
use
modifi
angiotensinii
although
sometim
seem
easi
vaccin
alreadi
develop
new
understand
microbiolog
immunolog
pathogen
new
technolog
minireview
clin
vaccin
immunol
march
guest
http
cviasmorg
provid
opportun
develop
vaccin
pathogen
elud
vaccin
control
addit
hiv
opportun
develop
new
vaccin
immun
program
diseas
develop
world
even
challeng
target
preval
underdevelop
countri
ebola
fever
dengu
hookworm
diseas
care
analysi
diseas
pattern
populac
also
point
need
new
immun
program
use
modif
establish
vaccin
respiratori
syncyti
viru
rsv
long
prospect
target
vaccin
develop
develop
vaccin
rsv
challeng
antibodi
insuffici
protect
inactiv
vaccin
gener
predominantli
antibodi
respons
promot
exagger
diseas
earli
formalininactiv
alumprecipit
vaccin
enhanc
diseas
temperaturesensit
liveattenu
intranas
vaccin
ineffect
jonathan
kleinevan
medimmun
inc
effect
describ
sever
differ
approach
taken
toward
rsv
vaccin
includ
subunit
vaccin
purifi
viral
glycoprotein
polypeptid
vaccin
dna
vaccin
express
f
g
glycoprotein
viru
live
viru
vector
includ
vaccinia
viru
bovin
parainfluenza
viru
adenoviru
express
f
g
glycoprotein
medimmun
inc
develop
coldpassag
temperaturesensit
attenu
viral
vaccin
passag
rsv
temperatur
less
viru
establish
upper
respiratori
infect
replic
warmer
environ
lung
phase
iii
trial
vaccin
promis
stress
import
keep
patent
lawyer
like
involv
vaccin
develop
process
secur
compani
invest
new
technolog
although
use
adenoviru
platform
develop
vaccin
differ
virus
initi
develop
way
provid
antigen
boost
prime
immun
respons
elicit
dna
vaccin
john
dong
genphar
inc
describ
use
adenoviru
platform
develop
vaccin
differ
virus
includ
hepat
b
hiv
marburg
ebola
dengu
virus
develop
adenoviru
strain
vector
genet
modifi
includ
gene
virus
immunogen
inject
aerosol
administr
high
dose
mixtur
adenovirus
express
one
viral
antigen
protein
administ
alon
supplement
adenovirus
express
cytokin
gamma
interferon
granulocytemacrophag
colonystimul
factor
suffici
high
dose
vaccin
develop
appropri
antibodyand
cellmedi
respons
consist
protect
administr
high
titer
adenovirusbas
vaccin
key
gener
protect
respons
rhesu
monkey
inject
hiv
vaccin
elicit
high
titer
antibodi
envelop
protein
similarli
vaccin
marburg
ebola
dengu
viru
promot
antibodyand
cellmedi
respons
although
vaccin
develop
motiv
benefit
mankind
primari
drive
remain
profit
sinc
vaccin
usual
made
pharmaceut
compani
maria
elena
bottazzi
describ
work
human
hookworm
vaccin
initi
hhvi
work
develop
deliv
recombin
vaccin
treat
prevent
hookworminduc
malnutrit
anemia
hookworm
diseas
one
three
major
soiltransmit
helminth
infect
preval
million
peopl
death
per
year
current
infect
treat
mebendazol
albendazol
drug
affect
adult
worm
larva
prevent
high
rate
reinfect
despit
great
benefit
vaccin
would
provid
lack
commerci
market
vaccin
requir
charit
government
fund
facil
nonprofit
govern
academ
institut
util
develop
hhvi
publicpriv
partnership
center
georg
washington
univers
oswaldo
cruz
foundat
brazil
london
school
hygien
tropic
medicin
sponsor
sabin
vaccin
institut
major
fund
bill
melinda
gate
foundat
hhvi
overcom
mani
challeng
develop
first
antiparasit
vaccin
includ
identifi
appropri
antigen
clone
express
antigen
demonstr
efficaci
vaccin
develop
good
manufactur
practic
method
vaccin
product
ancylostomasecret
larva
chosen
target
vaccin
develop
sinc
antibodi
protein
inhibit
larval
invas
vitro
studi
prevent
reduc
potenti
futur
infect
gene
necat
americanu
clone
express
secret
pichia
pastori
largescal
product
method
develop
vaccin
protein
purifi
ionexchang
chromatographi
adsorb
alhydrogel
vaccin
administ
within
week
druginduc
deworm
human
trial
alreadi
begun
pathway
develop
clinic
evalu
regulatori
approv
pathway
licensur
distribut
hookworm
vaccin
serv
model
exampl
develop
import
potenti
unprofit
vaccin
importantli
hhvi
demonstr
develop
vaccin
pull
within
academ
set
nelson
mandela
said
life
death
young
child
often
depend
whether
born
countri
vaccin
avail
issu
fundament
fair
new
vaccin
program
varicellazost
viru
vzv
pertussi
result
reevalu
immun
statu
diseas
preval
older
individu
discuss
meet
modifi
formul
children
varicellazost
viru
vaccin
develop
administr
adult
boost
immun
prevent
zoster
shingl
martin
wasserman
glaxosmithklin
describ
care
review
cdc
statist
indic
immun
respons
pertussi
elicit
inactiv
diphtheriapertussistetanu
dpt
vaccin
administ
infant
may
dissip
time
put
teen
risk
infect
diseas
adolesc
also
atrisk
group
fatal
meningococc
diseas
recommend
newli
develop
booster
tdap
combin
tetanu
diphtheria
acellular
pertussi
vaccin
new
meningococc
conjug
vaccin
teen
risk
diseas
minim
current
recommend
advisori
committe
immun
practic
vaccin
teenag
includ
booster
tetanu
diphtheria
catchup
vaccin
hepat
b
measlesmumpsrubella
mmr
varicella
million
teenag
miss
vol
minireview
march
guest
http
cviasmorg
least
one
recommend
vaccin
reformul
develop
combin
vaccin
streamlin
vaccin
administr
increas
util
quot
advisori
committe
immun
practic
ad
bonu
strong
adolesc
immun
platform
serv
driver
enhanc
prevent
improv
adolesc
health
care
promot
visit
physician
bring
vaccin
market
challeng
centuri
develop
approach
vaccin
product
retain
safeti
reliabl
reproduc
current
method
add
adapt
eas
scaleup
speed
lower
cost
new
advanc
technolog
provid
new
approach
increas
effici
develop
manufactur
test
vaccin
time
equal
money
aspect
vaccin
product
evalu
must
meet
highest
standard
fda
provid
guidelin
oversight
toward
maintain
standard
develop
new
vaccin
even
chang
procedur
requir
valid
fda
review
georg
robertson
dor
biopharma
inc
draw
experi
qualiti
control
lab
armi
merck
wyeth
stress
import
establish
depend
manufactur
laboratori
practic
vaccin
develop
procedur
follow
gdp
good
develop
practic
combin
glp
good
laboratori
practic
gmp
good
manufactur
practic
gcsp
good
common
sens
practic
manufactur
vaccin
requir
establish
valid
equip
valid
procedur
even
valid
individu
carri
procedur
stage
develop
process
ensur
vaccin
product
remain
retain
high
qualiti
throughout
valid
laboratori
procedur
import
part
process
assay
valid
respect
qualif
georg
robertson
said
accuraci
precis
specif
well
limit
detect
quantit
linear
rang
robust
reproduc
time
develop
valid
chang
raw
materi
procedur
system
personnel
requir
revalid
repres
major
expenditur
concern
valid
product
procedur
analyt
procedur
develop
system
standard
oper
procedur
chang
control
becom
necessari
promot
stabil
reduc
cost
ensur
qualiti
season
pandem
influenza
vaccin
special
case
vaccin
industri
due
need
new
vaccin
norman
baylor
director
offic
vaccin
research
review
center
biolog
evalu
research
discuss
fda
approach
meet
challeng
influenza
pandem
fda
respons
ensur
safeti
vaccin
assur
public
confid
defin
path
demonstr
vaccin
safeti
efficaci
qualiti
reproduc
manufactur
fda
start
work
industri
partner
earlier
stage
facilit
proper
path
toward
develop
test
process
vaccin
develop
acceler
mechan
approv
recognit
special
situat
influenza
vaccin
especi
pandem
flu
fda
care
look
legal
requir
develop
acceler
pathway
facilit
rapid
evalu
licensur
exampl
clinic
data
requir
approv
chang
viru
represent
accommod
annual
chang
endem
influenza
licens
manufactur
inactiv
flu
vaccin
surrog
marker
efficaci
use
test
annual
vaccin
eg
hemagglutinin
inhibit
activ
antihemagglutinin
antibodi
rather
protect
human
trial
use
surrog
marker
shorten
approv
time
vaccin
addit
fda
view
pandem
vaccin
made
use
licens
process
supplement
rather
new
licensesthi
speed
reduc
burden
cost
respons
pandem
influenza
outbreak
summari
fda
work
vaccin
industri
ensur
avail
qualiti
influenza
vaccin
product
influenza
vaccin
pose
greatest
challeng
product
licensur
chang
annual
everi
year
mani
million
fertil
chicken
egg
util
product
annual
influenza
vaccin
unfortun
depend
eggbas
vaccin
put
vaccin
suppli
risk
problem
suppli
egg
eg
adequ
advanc
plan
suffici
number
hen
suscept
hen
diseas
number
facil
capabl
product
addit
eggbas
manufactur
procedur
laborintens
take
larg
amount
space
perform
stringent
biosafeti
condit
biosafeti
level
avian
flu
outbreak
creat
addit
dilemma
put
lay
hen
risk
infect
henc
jeopard
suppli
egg
vaccin
product
peter
khouri
baxter
intern
describ
effort
develop
tissu
culturebas
vaccin
influenza
vaccin
choic
cell
line
growth
method
determin
growth
characterist
avail
lack
adventiti
agent
yield
viru
engin
aspect
relat
suspens
growth
growth
microcarri
baxter
intern
chose
develop
procedur
grow
larg
quantiti
vero
cell
african
green
monkey
kidney
cell
microcarri
serumfre
medium
bioreactor
influenza
vaccin
product
interestingli
vin
singh
brian
douglass
atcc
describ
effort
make
avail
earlier
passag
vero
cell
vaccin
product
comparison
eggbas
vaccin
vero
cell
vaccin
brought
onlin
quicker
less
plan
less
biosafeti
concern
work
virul
seed
virus
sinc
cell
cultur
perform
close
condit
vero
cell
alreadi
use
grow
inactiv
rabi
polio
vaccin
also
use
grow
virus
vaccin
includ
west
nile
enceph
sever
acut
respiratori
syndrom
coronavirus
baxter
intern
chiron
award
contract
cell
culturebas
vaccin
product
nation
health
servic
unit
kingdom
may
us
congress
divid
billion
award
among
glaxosmithklin
medimmun
inc
novarti
vaccin
diagnost
dynport
vaccin
co
solvay
pharmaceut
inc
develop
cell
culturebas
influenza
vaccin
baxter
intern
also
develop
autom
robot
procedur
harvest
cell
fertil
egg
make
chicken
embryo
cell
aggreg
altern
handl
tissu
cultur
condit
like
vero
cell
produc
vaccin
signific
pathogen
system
use
produc
vaccinia
viru
vaccin
tickborn
enceph
viru
switch
tissu
cultur
cellbas
vaccin
requir
consider
valid
test
approv
fda
tissu
cultur
cellbas
vaccin
util
make
vaccin
populac
mani
advantag
fertil
egg
method
may
provid
impetu
make
switch
money
money
legal
issu
challeng
centuri
find
money
fund
develop
new
vaccin
distribut
popul
need
take
lot
money
time
time
money
develop
produc
test
vaccin
brought
market
classic
rout
toward
fund
develop
new
compani
progress
seri
step
start
max
credit
card
approach
fff
group
friend
famili
fool
find
angel
invest
idea
ventur
capit
attract
busi
establish
usual
sourc
fund
vaccin
develop
invest
compani
stock
market
corpor
partner
big
pharma
uncl
sam
stage
invest
inventor
share
control
endeavor
becom
dilut
investor
pool
michael
salgal
toucan
capit
corp
note
investor
see
vaccin
industri
plagu
particularli
slow
riski
expens
develop
stage
toward
licensur
market
result
much
fund
vaccin
develop
govern
jill
hackel
wyeth
vaccin
describ
issu
must
consid
develop
vaccin
beyond
manufactur
boil
time
money
amount
time
requir
stage
vaccin
develop
increas
probabl
success
phase
develop
decreas
result
higher
risk
higher
cost
pharmaceut
compani
increasingli
limit
potenti
profit
cost
develop
vaccin
gone
million
million
continu
increas
industri
face
increas
regulatori
burden
due
evalu
new
technolog
increas
product
complex
necessari
zero
toler
risk
addit
differ
intern
requir
licensur
requir
redund
test
jill
hackel
suggest
one
way
eas
burden
involv
produc
season
influenza
vaccin
use
appropri
biomark
indic
vaccin
efficaci
earli
stage
vaccin
develop
lieu
protect
challeng
would
speed
research
phase
trial
care
coordin
trial
use
electron
data
manag
would
also
increas
effici
trial
importantli
care
earli
consult
fda
facilit
approv
process
fda
develop
critic
path
initi
develop
new
publicli
avail
scientif
technic
toolsinclud
assay
standard
comput
model
techniqu
biomark
clinic
trial
endpointsto
make
develop
process
effici
effect
like
result
safe
product
benefit
patient
recent
govern
fund
vaccin
develop
driven
fear
fear
bioterror
fear
blame
inact
concern
lost
revenu
due
absenc
due
ill
fear
potenti
threat
pandem
influenza
outbreak
garner
alloc
consider
fund
research
sever
differ
government
agenc
fear
threat
bioterror
elev
infecti
diseas
statu
militari
weapon
chang
definit
vaccin
program
militari
deterr
project
bioshield
answer
us
govern
came
creat
fund
activ
vaccin
develop
control
bioterror
agent
frank
rapoport
lawyer
mckenna
long
aldridg
llp
moniqu
k
mansoura
scientist
offic
research
develop
coordin
us
govern
describ
goal
project
bioshield
acceler
research
develop
purchas
avail
prioriti
medic
countermeasur
protect
us
popul
effect
chemic
biolog
radiolog
nuclear
threat
agent
basic
program
creat
vaccin
strateg
nation
stockpil
distribut
upon
need
sinc
contract
million
dose
anthrax
vaccin
award
contract
botulinum
antitoxin
nextgener
smallpox
vaccin
progress
estim
cost
smallpox
vaccin
billion
project
bioshield
spend
billion
stockpil
vaccin
anthrax
smallpox
botulinum
ebola
fever
plagu
redefinit
vaccin
develop
deterr
biowarfar
establish
project
bioshield
entic
militari
defens
industri
get
involv
vaccin
exampl
lockhe
aerospac
militari
defens
compani
bought
dyneport
vaccin
compani
extens
experi
lobbi
congress
fund
militari
defens
complex
may
chang
natur
futur
vaccin
develop
ogr
vaccin
industri
centuri
continu
liabil
lawsuit
vaccin
uniqu
clinic
intervent
administ
healthi
individu
elicit
immun
respons
individu
unpredict
zero
toler
side
effect
side
effect
unknown
outcom
basi
lawsuit
fear
cost
lawsuit
reduc
number
compani
make
vaccin
caus
price
vaccin
rise
enorm
exampl
cost
dpt
shot
rose
due
cost
litig
jame
wood
reed
smith
lawyer
defend
vaccin
drug
industri
litig
describ
vaccin
vaccin
industri
natur
target
litig
defin
pathway
court
ongo
lawsuit
base
use
thimeros
vaccin
side
effect
dpt
measl
vaccin
mention
interest
approach
legal
action
pursu
approach
base
potenti
consequ
possibl
acquisit
simian
viru
recipi
earli
polio
vaccin
caus
tumor
rodent
known
associ
human
cancer
wood
suggest
solut
could
congress
enact
feder
vaccin
act
would
creat
effici
method
provid
adequ
compens
vaccineinjur
person
also
protect
vaccin
produc
punit
damag
long
compani
show
complianc
fda
public
health
servic
rule
action
would
reduc
legal
cost
develop
market
vaccin
encourag
new
vaccin
program
vaccin
remain
primari
mean
prevent
diseas
reduc
health
care
cost
treatment
lost
work
time
due
sick
despit
greater
understand
immunolog
technolog
advanc
made
jeopardi
lose
acceler
vaccin
develop
occur
sinc
jenner
discoveri
due
incred
expens
small
profit
margin
great
risk
success
even
greater
risk
litig
present
meet
present
warn
optimist
suggest
improv
new
technolog
new
approach
product
greater
cooper
fda
vaccin
develop
enhanc
vaccin
develop
vaccin
industri
help
care
analysi
potenti
market
prior
develop
work
close
legal
product
peopl
earli
develop
process
care
design
vaccin
trial
ensur
applic
regul
multipl
countri
dialogu
fda
earli
develop
process
plan
deal
chang
feder
govern
help
mani
way
initi
tort
reform
help
removelessen
manufactur
liabil
develop
new
incent
earli
stage
invest
vaccin
develop
provid
tax
advantag
lower
capit
gain
rate
allow
saletransf
research
develop
tax
credit
reduc
regulatori
burden
vaccin
develop
without
compromis
safeti
categor
vaccin
within
orphan
drug
statu
clinic
trial
greater
util
surrog
indic
efficaci
especi
phase
trial
chang
patent
rule
promot
mandatori
patent
pool
extend
life
patent
time
lost
regulatori
process
increas
incent
return
invest
govern
facilit
vaccin
develop
enrich
fund
vaccin
research
develop
although
project
bioshield
given
consider
budget
fund
distribut
limit
number
compani
limit
defin
project
result
benefit
advanc
vaccin
field
also
limit
nih
remain
primari
fund
sourc
vaccin
project
academ
industri
review
crisp
comput
retriev
inform
scientif
project
databas
nih
project
past
year
indic
vaccin
project
repres
approxim
nih
project
compar
approxim
drug
pharmaceut
project
interestingli
number
nih
intramur
vaccin
project
suggest
higher
prioriti
within
nih
campu
appli
extramur
project
addit
mani
approach
nih
current
take
enhanc
vaccin
develop
develop
could
reach
increas
number
includ
small
busi
innov
research
sbir
small
busi
technolog
transfer
sttr
studi
section
review
immunologyvaccin
project
increas
represent
review
studi
section
come
vaccin
segment
industri
increas
expand
number
request
applic
specif
vaccin
addit
greater
recognit
paid
fund
sourc
fda
toward
vaccin
elicit
protect
antibodi
therapi
noninfecti
diseas
autoimmun
allergi
cancer
therapi
diseas
alzheim
dementia
obes
smoke
drug
abus
hypertens
mani
develop
made
within
vaccin
industri
interestingli
rel
new
technolog
enter
vaccin
market
mani
diseas
target
vaccin
prevent
treatment
fund
risk
limit
profitreturn
reduc
initi
develop
vaccin
even
centuri
go
requir
team
effort
differ
constitu
repres
vaccin
thing
consid
meet
present
minireview
fourth
annual
meet
held
novemb
washington
dc
http
gtcbiocomconfpageasp
